Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Onxeo S.A.    ONXEO   FR0010095596

ONXEO S.A.

(ONXEO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
0.762(c) 0.787(c) 0.741(c) 0.765(c) 0.76(c) Last
1 075 823 628 750 493 759 234 184 94 220 Volume
+4.67% +3.28% -5.84% +3.24% -0.65% Change
More quotes
Financials
Sales 2020 1,69 M 2,01 M 2,01 M
Net income 2020 -5,33 M -6,36 M -6,36 M
Net cash position 2020 10,3 M 12,3 M 12,3 M
P/E ratio 2020 -9,50x
Yield 2020 -
Sales 2021 8,25 M 9,85 M 9,85 M
Net income 2021 -4,85 M -5,79 M -5,79 M
Net cash position 2021 1,45 M 1,74 M 1,74 M
P/E ratio 2021 -12,7x
Yield 2021 -
Capitalization 59,3 M 70,6 M 70,7 M
EV / Sales 2020 29,0x
EV / Sales 2021 7,01x
Nbr of Employees 30
Free-Float 88,9%
More Financials
Company
Onxeo is a biotechnology company specializing in the development of innovative oncology medicines based on DNA-targeting and epigenetics, two of the most anticipated mechanisms of action in the treatment of cancer today. The group focuses on the development of innovative first-in-class or disruptive compounds (company-owned, acquired or licensed) from translational research to clinical proof of concept in humans, a... 
Sector
Pharmaceuticals
Calendar
11/24Presentation
More about the company
Notations Surperformance© of Onxeo S.A.
Trading Rating : - Investor Rating :
More Ratings
All news about ONXEO S.A.
11/09ONXEO S A : Announces Completion of Patient Enrollment in DRIIV-1b Study and Pos..
PU
11/09ONXEO S A : Announces Completion of Patient Enrollment in DRIIV-1b Study and Pos..
BU
11/09ONXEO : Announces Completion of Patient Enrollment in DRIIV-1b Study and Positi..
AQ
11/09Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Posit..
GL
10/22ONXEO : Receives Notice of Intent to Grant a New Patent Enhancing the Protection..
AQ
10/22ONXEO : Receives Notice of Intent to Grant a New Patent Enhancing the Protection..
BU
10/22Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protectio..
GL
10/21ONXEO : Announces Enrollment of First Patient in Phase Ib/II Study Revocan
AQ
10/21Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
GL
10/21ONXEO S A : Announces Enrollment of First Patient in Phase Ib/II Study Revocan
BU
09/30ONXEO S.A. : Monthly statement on outstanding equity shares and voting rights
CO
09/29ONXEO : Publication of the 2020 Half-yearly Financial Report
BU
09/24ONXEO S A : 2020 Half-Yearly Financial Report
PU
09/17Onxeo Reports its Financial Results for the First Half of 2020 and Provides a..
GL
09/17ONXEO : Reports its Financial Results for the First Half of 2020 and Provides an..
AQ
More news
News in other languages on ONXEO S.A.
11/23ONXEO : plus forte baisse du SRD à la clôture du lundi 23 novembre 2020
11/10Les derniers seront les premiers
11/10EN DIRECT DES MARCHES : Unibail, Saint-Gobain, Neoen, Rothschild, Adidas, Boeing..
11/09ONXEO S A : annonce la fin du recrutement des patients dans l'étude DRIIV-1b et ..
10/22ONXEO : reçoit une notification d'intention de délivrance d'un nouveau brevet re..
More news
Chart ONXEO S.A.
Duration : Period :
Onxeo S.A. Technical Analysis Chart | ONXEO | FR0010095596 | MarketScreener
Technical analysis trends ONXEO S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,22 €
Last Close Price 0,76 €
Spread / Highest target 60,5%
Spread / Average Target 60,5%
Spread / Lowest Target 60,5%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Danièle Guyot-Caparros Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ONXEO S.A.36.94%71
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273